Covidien delivers 20,000th ForceTriad

Wednesday, January 26, 2011

Covidien (Boulder) announced the delivery of the Company's 20,000th ForceTriad™ energy platform. The Dongzhimen Hospital, an affiliate of Beijing University of Chinese Medicine, in Beijing, China, took delivery of the device earlier this month. Known for its teaching and clinical research, Dongzhimen Hospital embraces both Chinese and Western medicine in serving the healthcare needs of its patients and the community. Since its launch in 2006, the ForceTriad platform has been placed into service in hospitals in 94 countries.  

Inviragen announces MOU

Wednesday, January 26, 2011

Inviragen, Inc. (Fort Collins) and the Duke-National University of Singapore Graduate Medical School ("Duke-NUS") announced today that they have completed a memorandum of understanding (MOU) to establish a partnership between the two organizations. The goal of the partnership is to better understand how emerging infectious diseases are transmitted and how transmission can be prevented. Through this collaborative program, Inviragen and Duke-NUS aim to advance the research and development of vaccines against infectious diseases such as dengue fever, hand, foot and mouth disease and chikungunya.

Weekly Legislative Report including SB11-047

Monday, January 24, 2011

CBSA's Policy Committee and Board have been working diligently on developing state policy priorities and working with our lobbyist, Erin Silver on creating two funding bills this upcoming session. The "Colorado Bioscience and Clean Technology Innovation Reinvestment Act," (SB11-047) sponsored by Senator Rollie Heath and Representatives Cheri Gerou and Jim Riesberg, would provide an additional funding stream for our Bioscience Discovery Evaluation Grant program (HB1001-08) that is due to sunset in 2012.    

FDA 510(k) Plan

Wednesday, January 19, 2011
The FDA's Center for Devices and Radiological Health (CDRH) released a report summarizing public comments related to initial recommendations released in August 2010, as well as a plan containing 25 actions for implementation in 2011 related to 510(k) approval.  (Full report)  Both AdvaMed and the MDMA released statements in response.
AdvaMed Statement   
Continue Reading

Allos Therapeutics publishes data

Wednesday, January 19, 2011

WESTMINSTER, Colo., Jan 19, 2011 (BUSINESS WIRE) -- Allos Therapeutics, Inc. (NASDAQ: ALTH) today announced that the Journal of Clinical Oncology has published data from the Company's pivotal Phase 2 PROPEL study demonstrating clinical activity of FOLOTYN® (pralatrexate injection) in patients with relapsed or refractory peripheral T-cell lymphoma (PTCL). These published results are from an updated analysis of the PROPEL study, which was the basis of the September 2009 U.S. Food and Drug Administration (FDA) accelerated approval of FOLOTYN - the only single-agent approved for the treatment of patients with relapsed or refractory PTCL. This indication is based on overall response rate. Clinical benefit such as improvement in progression-free survival or overall survival has not been demonstrated.  

Dwayne Romero named ED of OEDIT

Wednesday, January 19, 2011

DENVER — Gov. John Hickenlooper announced today Dwayne Romero will be Executive Director of the Office of Economic Development and International Trade. 

miRagen CU TTO Company of the Year

Tuesday, January 18, 2011

BOULDER, Colo., Jan 18, 2011 (BUSINESS WIRE) -- miRagen Therapeutics, Inc., a biopharmaceutical company focused on improving patients' lives by developing innovative microRNA (miRNA)-based therapeutics for cardiovascular and muscle disease, announced today that it is the recipient of the University of Colorado (CU) Technology Transfer Office Bioscience Company of the Year award. The award will be conferred this evening at the CU Technology Transfer Annual Awards Banquet in Denver.  

AlloSource enters agreement

Thursday, January 13, 2011

AlloSource (Centennial) has entered into an agreement to distribute Wright Medical's (Arlington, TN) novel bone graft product called FusionFlex Bone Matrix.  The financial terms of the deal were not disclosed.  

Allos Therapeutics reports financial

Tuesday, January 11, 2011

Allos Therapeutics (Westminster) reported financial results for 2010 and key priorities for 2011.  Included among the results were sales of $11.8M for FOLOTYN for the fourth quarter of the year, a 27% sequential increase over the previous quarter. 

Luca Technologies appointment

Tuesday, January 11, 2011

Luca Technologies Inc. (Golden), the leading developer of energy farming technologies and producer of sustainable natural gas, today announced the appointment of Matt Micheli Senior Corporate Counsel and Head of Government and Regulatory Affairs. Effective today, Mr. Micheli will be responsible for the advancement of Luca Technologies' regulatory affairs and permitting processes.